Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » GenMark Diagnostics Downgraded by JP Morgan to Neutral

GenMark Diagnostics Downgraded by JP Morgan to Neutral

Dec 11, 2019
|
staff reporter

NEW YORK – JP Morgan said Wednesday that it has downgraded GenMark Diagnostics' stock to Neutral from Overweight and lowered the molecular diagnostic firm's December 2020 stock price target to $7 from $11.

The investment bank said Carlsbad, California-based GenMark experienced healthy momentum this year in placements of its ePlex molecular diagnostic analyzers, but reimbursement and competitive pressures pose a risk to its business outlook.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

German Shepherd's Own Sequence

A German shepherd called Nala has had her genome sequenced.

And Now Serology Tests

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Young at Brain

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

Science Paper Examines Factors to Identify Metastatic Prostate Cancer Responsive to Checkpoint Inhibitors

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

What's Popular?

In Business News

  1. Ipsum Diagnostics Coronavirus Test Gets FDA Emergency Use Authorization

  2. A. Menarini to Distribute Credo Diagnostics Coronavirus Assay Kit, Respiratory Infection Assays

  3. LexaGene Shifts Gears to Prepare Viral RT-qPCR Panel for FDA Emergency Submission

  4. Color Gears Up to Enter COVID-19 Testing Space

  5. Amgen, Adaptive Biotechnologies Partner on Drug Discovery for COVID-19

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.